What role does CYP2D6 play in blood sugar?

CYP2D6 is a cytochrome P450 enzyme primarily involved in the metabolism of numerous drugs. It does not play a direct role in blood sugar regulation. However, it can indirectly affect glucose levels by metabolizing medications such as beta-blockers, antidepressants, and antipsychotics, which may influence insulin sensitivity or glucose production. Genetic variants in CYP2D6 (poor, intermediate, extensive, or ultrarapid metabolizer phenotypes) alter drug clearance and thus the clinical effect of these drugs, potentially impacting glycemic control. Yet, strong human evidence linking CYP2D6 polymorphisms directly to fasting glucose, insulin resistance, or diabetes risk is lacking. The evidence is mostly mechanistic and pharmacogenetic. For blood sugar management, lifestyle factors and genes with established roles in glucose homeostasis (e.g., TCF7L2, GCK) are far more important. Caveat: consumer DNA tests reporting CYP2D6 status should not be interpreted as predictive of diabetes or blood sugar problems without clinical context.